17,261 trials
Pain · Low Back Pain · Back Pain
Primary: Change From Baseline in 11-point Numerical Rating Scale (NRS) at Week 12 — 6.9; 6.9; -3.0; -2.9 Units on a scale
Substance Abuse
Primary: Substance Use — 45.67; 53.60; 49.38 percent days of drug use
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Response — 47.5; 29.6; 51.6; 63.3 percentage of participants
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Brain Injury · Intracranial Pressure
Primary: Lactate/Pyruvate (L/P)Ratio — 103.1; 33.8 ratio
Lymphoma, Non-Hodgkin's
Primary: Participants Categorized by Best Response as Determined by Central Review — 7; 21; 40; 71 Participants
Prostatic Neoplasms
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Best Response — 51.7; 60.2; 28.1 Percentage of participants
Prostatic Cancer
Primary: Efficacy of Quinacrine, Based on Prostate Specific Antigen (PSA) Response in Patients With Androgen-independent Metastatic Prostate Cancer — 1 Participants
Breast Cancer · Metastatic Breast Carcinoma · Invasive Breast Carcinoma
Primary: Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products — 9 participants
Prostate Cancer · Genetic Polymorphism
Primary: Progression Free Survival. — 6.0 Months
Melanoma (Skin)
Primary: Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST — 3 participants
Soft Tissue Sarcoma
Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs
Dry Eye Syndromes
Primary: Percentage of Participants With Systemic Adverse Events (AEs) — 27.7; 8.7; 29.8; 27.1 percentage of participants
Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Adverse Events — 195 Participants
Neuropathic Pain · Reflex Sympathetic Dystrophy · Peripheral Neuropathy
Primary: Participants With 30% or Greater Reduction in Pain Intensity — 61; 57; 26 percentage of participants